SGLT2 inhibitors as metabolic modulators: beyond glycemic control in type 2 diabetes

SGLT2 inhibitors as metabolic modulators: beyond glycemic control in type 2 diabetes

Type 2 diabetes mellitus (T2DM) is a complex metabolic disorder, and its management has evolved from mere glycemic control to multitarget metabolic regulation. Sodium–glucose cotransporter 2 inhibitors (SGLT2is) have demonstrated extensive pleiotropic effects in treating T2DM, and its complications...

Full description

Saved in:

Bibliographic Details
Main Authors:	Qian Wu, Jian Zhang, Fuli Zhang, Dongnan Li
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-06-01
Series:	Frontiers in Endocrinology
Subjects:	SGLT2is metabolic regulation type 2 diabetes cardiovascular protection combination therapy
Online Access:	https://www.frontiersin.org/articles/10.3389/fendo.2025.1601633/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Doxorubicin-Induced Cardiotoxicity and the Emerging Role of SGLT2 Inhibitors: From Glycemic Control to Cardio-Oncology
by: Iacob-Daniel Goje, et al.
Published: (2025-05-01)

Research Progress of SGLT2 Inhibitors in Cancer Treatment
by: Miao X, et al.
Published: (2025-01-01)

Impact of SGLT2 Inhibitors on Cardiovascular Risk Scores, Metabolic Parameters, and Laboratory Profiles in Type 2 Diabetes
by: Nazif Yalçın, et al.
Published: (2025-04-01)

Advances in the mechanism of action of SGLT2 inhibitors on the kidney
by: JI Ying, et al.
Published: (2020-01-01)

The Influence of Performance Status, Inflammation, and Nutrition on the Impact of SGLT2 Inhibitors on Cancer Outcomes
by: Diego Rivas‐Otero, et al.
Published: (2025-03-01)

Double Duty: SGLT2 Inhibitors as Cardioprotective and Anticancer Allies
by: Linda Piras, et al.
Published: (2024-11-01)

Expanding the Use of SGLT2 Inhibitors in T2D Patients Across Clinical Settings
by: Alessandro Cuttone, et al.
Published: (2025-05-01)

Cardiovascular Outcome of the SGLT2 Inhibitor in Acute Myocardial Infarction: A Meta-Analysis
by: Siqi Hu, et al.
Published: (2025-02-01)

Investigating the effect of SGLT2 inhibitors on cardiovascular related health status in HFmrEF and HFpEF: systematic review and meta analysis
by: Tabitha Kusi-Yeboah, et al.
Published: (2025-07-01)

A decade of progress in type 2 diabetes and cardiovascular disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists – a comprehensive review
by: David Aristizábal-Colorado, et al.
Published: (2025-07-01)

Antioxidant Effects of SGLT2 Inhibitors on Cardiovascular–Kidney–Metabolic (CKM) Syndrome
by: Juan Guerrero-Mauvecin, et al.
Published: (2025-06-01)

Ketoacidosis as unexpected adverse reaction SGLT<sub>2</sub> inhibitor
by: T. M. Bukatina, et al.
Published: (2018-02-01)

Correction: A decade of progress in type 2 diabetes and cardiovascular disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists – a comprehensive review
by: David Aristizábal-Colorado, et al.
Published: (2025-08-01)

Is the Impact of Sodium–Glucose Co-Transporter 2 (SGLT2) Inhibitors on Bone Metabolism and Fracture Incidence a Class or Drug Effect? A Narrative Review
by: George I. Lambrou, et al.
Published: (2025-04-01)

Cardiac Fibrosis: Mechanistic Discoveries Linked to SGLT2 Inhibitors
by: Filip Rolski, et al.
Published: (2025-02-01)

Is cancer incidence modified by SGLT2 inhibitors?
by: Lev M. Berstein
Published: (2019-10-01)

Impact of SGLT-2 Inhibitors on Biomarkers of Heart Failure
by: Dana Darwish, et al.
Published: (2025-06-01)

Severe hyperchloremic metabolic acidosis with SGLT2 inhibitors in patients with urinary diversion
by: Carolina Gomes, et al.
Published: (2025-05-01)

Severe hyperchloremic metabolic acidosis with SGLT2 inhibitors in patients with urinary diversion
by: Carolina Gomes, et al.
Published: (2025-05-01)

SGLT2 Inhibitors in Patients with Chronic Kidney Disease and Heart Disease: A Literature Review
by: Abhishek Kansara, et al.
Published: (2022-09-01)

Effectiveness of SGLT2 inhibitors compared to sulphonylureas for long-term glycemic control in type 2 diabetes: A meta-analysis
by: Zhouhong Zhan, et al.
Published: (2025-07-01)

New Insights into the Role of SGLT-2 Inhibitors in the Prevention of Dementia
by: Cheng-Hsien Hung, et al.
Published: (2024-12-01)

SGLT-2 inhibitors in the management of acute decompensated heart failure
by: Anastasia E. Poskakalova, et al.
Published: (2024-11-01)

A study on the pharmacovigilance of various SGLT-2 inhibitors
by: Yanwen Dong, et al.
Published: (2025-01-01)

Correspondence: Improved glycemic and weight control with Dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting. The AWARE-2 study
by: Chang-Yuan Hsu, et al.
Published: (2025-03-01)

Impact of sodium-glucose cotransporter-2 inhibitors on aging biomarkers and plasma ceramide levels in type 2 diabetes: beyond glycemic control
by: Youssef M. Shalaby, et al.
Published: (2025-12-01)

Effect of SGLT2 inhibitors on the course of chronic heart failure in patients with type 2 diabetes mellitus
by: A. N. Payudis, et al.
Published: (2022-10-01)

SGLT2 inhibitors reduce the risk of renal failure in CKD stage 5 patients with Type 2 DM
by: Birdie Huang, et al.
Published: (2025-02-01)

Prevalence and thrombotic risk of SGLT-2 inhibitor-associated erythrocytosis: a retrospective cohort study
by: Ji Yun Lee, et al.
Published: (2025-07-01)

Evidence-based SGLT2 inhibitor and GLP-1 receptor agonist use by race in the VA healthcare system
by: Demetria M. Bolden, et al.
Published: (2025-06-01)

Mottling as an early sign of euglycemic ketoacidosis induced by SGLT-2 inhibitors
by: Besard Memeti, et al.
Published: (2025-03-01)

The protective role of SGLT2 inhibitors on aortic aneurysm mediated by oxidative stress and inflammation in type 2 diabetes mellitus
by: Rujie Zheng, et al.
Published: (2025-02-01)

Canagliflozin: from glycemic control to improvement of cardiovascular and renal prognosis in patients with type 2 diabetes mellitus. Resolution of Advisory Board
by: M. V. Shestakova, et al.
Published: (2022-01-01)

Factors influencing the selection of an SGLT2i vs. a GLP-1RA as cardioprotective agent in patients with type 2 diabetes
by: Shubham Agarwal, et al.
Published: (2025-05-01)

Development of an Efficient Process for a Key Synthetic Intermediate of the SGLT2 Inhibitor LH-1801
by: Jun Qu, et al.

SGLT2 inhibitors in autoimmune diseases: emerging therapeutic potential and clinical challenges
by: Taimin Luo, et al.
Published: (2025-07-01)

Position of SGLT2i in prediabetes: A systematic review of literature
by: Kaushik Biswas, et al.
Published: (2025-04-01)

Exploring the Cardiorenal Benefits of SGLT2i: A Comprehensive Review
by: Angelica Cersosimo, et al.
Published: (2024-10-01)

Association between SGLT-2 inhibitors and suicide risk in type 2 diabetes and bipolar: a real-world cohort study
by: En-Wei Chang, et al.
Published: (2025-06-01)

Unveiling the anticancer potential of SGLT-2 inhibitors: mechanisms and prospects in clinical oncology—a narrative review
by: Jiaxin Li, et al.
Published: (2025-06-01)